Skip to main content
SpringerLink
Log in

Benign Prostatic Hyperplasia and LUTS

  • Chapter
Men's Health

Abstract

Benign prostatic hyperplasia is a histopathologic finding in prostates in aging men, and LUTS is a complex of voiding symptoms also seen in aging men but not exclusively. Also, BPH is not the sole cause of LUTS in men. Historically terms like prostatism were used when both of these conditions were present at the same time, but it is now well established that there is no cause and effect relationship and thus this term is no longer used. LUTS can be caused by bladder dysfunction, polyuria, sleep disorders, and a number of other systemic disorders. BPH represents a significant burden in aging men due to frequently associated LUTS, which have an impact on the quality of life. BPH is also a progressive disease in most men, mainly characterized by worsening of LUTS over time. Progression in some patients can result in serious outcomes such as acute urinary retention and need for BPH-related surgery. The evaluation of BPH and LUTS is well established, but the treatment options continue to evolve. The goals of therapy for BPH are not only to improve bothersome LUTS but to protect the bladder function and identify patients at risk of complications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McNeal J. Pathology of benign prostatic hyperplasia: insight into etiology [review]. Urol Clin North Am. 1990;17:477–86.

    CAS  PubMed  Google Scholar 

  2. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987;317:599–604.

    Article  CAS  PubMed  Google Scholar 

  3. Walsh PC, Hutchins GM, Ewing LL. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supernormal. J Clin Invest. 1983;72:1772–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Lin VK, Wang D, et al. Myosin heavy chain gene expression in normal and hyperplastic human prostate tissue. Prostate. 2000;44:193–203.

    Article  CAS  PubMed  Google Scholar 

  5. Berry SJ, Coffey DS, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9.

    CAS  PubMed  Google Scholar 

  6. Chute CG, Panser LA, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85–9.

    CAS  PubMed  Google Scholar 

  7. Jacobsen SJ, Girman CJ, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol. 1996;155:595–600.

    Article  CAS  PubMed  Google Scholar 

  8. Wei J, Calhoun E, Jacobsen S. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173:1256.

    Article  PubMed  Google Scholar 

  9. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803.

    Article  PubMed  Google Scholar 

  10. Garraway WM, Armstrong C. Follow-up of a cohort of men with untreated benign prostatic hyperplasia. Eur Urol. 1993;24:313–8.

    CAS  PubMed  Google Scholar 

  11. Abrams P. Objective evaluation of bladder outlet obstruction [review]. Br J Urol. 1995;76:11–5.

    Article  PubMed  Google Scholar 

  12. Caine M, Schuger L: The “capsule” in benign prostatic hypertrophy. Publication No. 87–2881. Bethesda (MD): U.S. Department of Health and Human Services; 1987.

    Google Scholar 

  13. Shapiro E, Becich MJ. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol. 1992;147:1293–7.

    CAS  PubMed  Google Scholar 

  14. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004;171:1029–35.

    Article  CAS  PubMed  Google Scholar 

  15. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53:1228–35.

    Article  PubMed  Google Scholar 

  16. Lepor H, Williford W, Barry M. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;33:533.

    Article  Google Scholar 

  17. McConnell JD, Roehrborn C. The long-term effects of doxazosin, finasteride and the combination on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2385–96.

    Article  Google Scholar 

  18. Oesterling JE, Kaplan SA, Epstein HB. The North American experience with the UroLume endoprosthesis as a treatment for benign prostatic hyperplasia: long-term results. The North American UroLume Study Group. Urology. 1994;44:353–62.

    Article  CAS  PubMed  Google Scholar 

  19. Bruskewitz R, Issa M, Roehrborn CG. A prospective, randomised, 1-year clinical trial comparing transurethral needle ablation (TUNA) to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol. 1998;159:1588–94.

    Article  CAS  PubMed  Google Scholar 

  20. Wheelahan J, Scott NA, Cartmill R. Minimally invasive non-laser thermal techniques for prostatectomy: a systematic review. BJU Int. 2000;86:977–88.

    Article  CAS  PubMed  Google Scholar 

  21. Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Thomas Brown B, McVary KT. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: The L.I.F.T. study. J Urol. 2013;190(6):2161–7.

    Article  PubMed  Google Scholar 

  22. Kabalin J. Holmium:YAG laser prostatectomy: results of a US pilot study. J Endourol. 1996;10:453–7.

    Article  CAS  PubMed  Google Scholar 

  23. Anson K, Nawrocki J, Buckley J. A multicenter randomised prospective study of endoscopic laser ablation versus transurethral resection of the prostate. Urology. 1995;43:305–10.

    Article  Google Scholar 

  24. Cowles RS, Kabalin JN, Childs S. A prospective randomised comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology. 1995;46:155–8.

    Article  PubMed  Google Scholar 

  25. Gilling P, Cass C, Cresswell M. The use of the holmium laser in the treatment of benign prostatic hyperplasia. J Endourol. 1996;10:459–61.

    Article  CAS  PubMed  Google Scholar 

  26. Sandhu JS, Ng C, Vanderbrink BA. High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology. 2004;64:1155–9.

    Google Scholar 

  27. Naspro R, Bachmann A, Gilling P. A review of the recent evidence (2006–2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol. 2009;55:1345–57.

    Article  PubMed  Google Scholar 

  28. Wasson JH, Reda DJ, Bruskewitz RC. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med. 1995;332:75–9.

    Article  CAS  PubMed  Google Scholar 

  29. Adam C, Hofstetter A, Deubner J. Retropubic transvesical prostatectomy for significant prostatic enlargement must remain a standard part of urology training. Scand J Urol Nephrol. 2004;38:472.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Stanford University Hospital, 875 Blake Wilbur Avenue, Stanford, CA, 94305, USA

    Harcharan Gill M.D.

Authors
  1. Harcharan Gill M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harcharan Gill M.D. .

Editor information

Editors and Affiliations

  1. Vista Urology & Pelvic Pain Partners, San Jose, California, USA

    Jeannette M Potts

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gill, H. (2016). Benign Prostatic Hyperplasia and LUTS. In: Potts, J. (eds) Men's Health. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3237-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3237-5_12

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-3236-8

  • Online ISBN: 978-1-4939-3237-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation